Direct costs were approximately USD 2.8 billion, down 34.3% sequentially and 51.1% year over year. Digital asset sales revenue was USD 2.7 billion, down 35.2% sequentially and 52% year over year. After digital asset sales costs, the company generated approximately USD 4.2 million, aMarginof …
The company said the increase was primarily driven by higher large project volume, including USD 77.8 million from its current large generation project.
The company reported grant revenue of USD 20 thousand for the quarter, compared with USD 209 thousand. Grant revenue for all periods presented relates to work for the National Institutes of Health. The filing states that the company'sAlphatherapyBusinessis in the clinical stage and that …
Interest income, which includes amortization of upfront fees, decreased to USD 35.6 million from USD 38.7 million, primarily due to a decline in benchmark rates and restructurings of certainDebtinvestments. Dividend income decreased to USD 0.9 million from USD 2.2 million due to lower dividend …
The company reported a net loss attributable to the company of USD 2.0 million, compared withNet Incomeof USD 1.5 million a year earlier. Operating income was USD 10.5 million, up USD 1.1 million from USD 9.4 million, and theGAAPOperating Marginwas 2.6% compared with 4.8%.
The company's chief financial officer said adjusted operatingEarnings Per Sharewere USD 2.02 higher than in the third quarter of last year, with accretion from Calpine as the key driver. Higher capacity prices in PJM and commercial performance also contributed, partly offset by lower production …
Net loss from continuing operations was USD 38.9 million, compared with USD 44.5 million, and net loss per share from continuing operations was USD 0.25, compared with USD 0.38. For the nine months, net revenue was USD 40.9 million, compared with USD 29.4 million, …
Industrial adjusted EBIT was USD 202 million, up 94%, and the adjusted industrial EBIT margin improved 270 basis points to 5.5%. FreeCash Flowfrom industrial activities was an outflow of USD 10 million, an improvement of USD 178 million year over year.
Management said the decline in revenue was primarily driven by the sale of Brasada Ranch, which accounted for USD 10 million of the decline.
The existing portfolio generated approximately 67% of recurring revenue growth, with acquisitions completed during 2025 contributing approximately 33%.